Current options for the therapy of chronic hepatitis B infection

Ono‐Nita, Suzane Kioko; Kato, Naoya; Shiratori, Yasushi; Omata, Masao

doi:10.1007/s11908-996-0036-2

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lamivudine is a nucleoside reverse transcriptase inhibitor and is currently used in many countries for the hepatitis B treatment. Despite the potent action of this drug, the development of viral resistance prompted the search for new therapeutic agents and new strategies to treat hepatitis B [1]. Adefovir is a new nucleoside analogue that has shown to be effective in cases of lamivudine-resistant virus [2-4].…”

Section: Introductionmentioning

confidence: 99%

Searching for chronic hepatitis B patients in a low prevalence area – role of racial origin

et al. 2004

Self Cite

View full text Add to dashboard Cite

BackgroundClinical studies for testing new drugs against hepatitis B ought to be carried out in low prevalence areas despite difficulties on patient recruitment. In such areas, relatives of chronic hepatitis B patients are considered to be at risk of acquiring the hepatitis B virus (HBV). The aim of this study was to evaluate the prevalence of HBV markers (anti-HBc, HBsAg and anti-HBs) in familial members of chronic hepatitis B (CHB) patients according to their origin (Asian or Western) in a low prevalence area, the city of São Paulo, Brazil.MethodsTwenty three Asian CHB probands and their 313 relatives plus 31 CHB probands of Western origin and their 211 relatives were screened for HBV serological markers; the study was carried out in the outpatient clinic of the University of São Paulo School of Medicine.ResultsMother to child transmission was greater in the Asian group whereas sexual transmission was more frequent in the Western group (p < 0.0001). Anti-HBc was positive in 90% and 57% of the Asian and Western parents (p = 0.0432) and in 97% and 33% of the Asian and Western brothers (p = 0.0001), respectively. HBsAg was more frequent among the Asian (66%) than the Western (15%) mothers (p = 0.0260) as well as among the Asian (81%) than the Western (19%) brothers (p = 0.0001). We could detect 110 new HBsAg-positive subjects related to the 54 index patients, being the majority (81%) of Asian origin.ConclusionIn low prevalence area of hepatitis B, family members and household contacts of chronic HBV carriers are at high risk for acquiring hepatitis B.

show abstract

Section: Introductionmentioning

confidence: 99%

Searching for chronic hepatitis B patients in a low prevalence area – role of racial origin

et al. 2004

Self Cite

View full text Add to dashboard Cite

show abstract

Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis

Kim

Abreu

Nakagawa

et al. 2015

Journal of Viral Hepatitis

View full text Add to dashboard Cite

SUMMARY. Conventional interferon alfa and nucleos(t)ide analogues, such as lamivudine, are frequently used for chronic hepatitis B (CHB) treatment, but are associated with adverse effects and viral resistance. Here we performed a systematic review and meta-analysis evaluating all studies of pegylated interferon alfa (PEG-IFNa) treatment in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients with CHB. We searched electronic databases -PubMed, EMBASE, Cochrane Library and LILACS -for randomized controlled trials evaluating PEGIFNa therapy between 1999 and September 2014. Virological response was the primary outcome. We identified 14 studies involving 2829 patients. Our analysis revealed that PEG-IFNa + lamivudine combination therapy produced better virological and biochemical responses than PEGIFNa monotherapy in HBeAg-positive and HBeAg-negative patients at the end of treatment. PEG-IFNa + adefovir dipivoxil achieved better seroconversion rate than PEG-IFNa in HBeAg-positive patients at the end of treatment. The present findings demonstrated a beneficial response rate following PEG-IFNa combination therapy with nucelos(t)ides among HBeAg-positive and HBeAg-negative patients with CHB. Further trials are needed to investigate simultaneous and sequential therapy strategies.

show abstract

Current options for the therapy of chronic hepatitis B infection

Cited by 2 publications

References 49 publications

Searching for chronic hepatitis B patients in a low prevalence area – role of racial origin

Searching for chronic hepatitis B patients in a low prevalence area – role of racial origin

Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis

Contact Info

Product

Resources

About